Summit Therapeutics Inc. — Director's Dealing 2025

Sep 12, 2025

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Summit Therapeutics Inc. (SMMT)
CIK: 0001599298
Period of Report: 2025-09-10

Reporting Person: Zanganeh Mahkam (Director, Co-Chief Executive Officer, 10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2025-09-10	Common Stock	P	333394	$17.68	Acquired	556088090	Indirect
2025-09-11	Common Stock	P	5000	$18.07	Acquired	556093090	Indirect

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	10199776	Indirect
Common Stock	25457666	Indirect
Common Stock	50000	Indirect
Common Stock	31000	Direct

Footnotes

F1: The reported price in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $17.49 to $17.89 per share, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

F2: The Reporting Person disclaims beneficial ownership of these securities, except to the extent of her pecuniary interest therein, if any, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 or for any other purpose